{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-23-000006","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.743367+00:00","generated_at":"2026-06-20T18:09:17.060331+00:00","sec_items":["2.02","7.01","5.03","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GeneDx (formerly Sema4) eyes 37-40% revenue growth to ~$170-173M in 2022; guides 2023 rev $205-220M","bullets":["Preliminary pro forma 2022 revenue $170-173M, up 37-40% YoY from $123.7M.","Pro forma test result volume >180,000 (+23% YoY); adjusted gross margin 38-41% (up from 34%).","2023 guidance: revenue $205-220M; cash burn for continuing ops $95-110M; targeting profitability in 2025.","Name changed to GeneDx Holdings Corp.; common stock begins trading under WGS on Jan 10, 2023.","CEO highlights combination of GeneDx and Centrellis platforms to accelerate precision medicine."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-23-000006","json":"https://secwatch.observer/filing/0001818331-23-000006.json","markdown":"https://secwatch.observer/filing/0001818331-23-000006.md","text":"https://secwatch.observer/filing/0001818331-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/smfr-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:09:17.060331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e760566aeeafe812c13e3dedb2ec9e1cc1601ea","claim":"GeneDx Holdings Corp. reported 2022 results: revenue $170-173 million.","evidence_excerpt":"Preliminary 2022 Financial Results (Unaudited) Excluding revenues and costs from the previously announced exited reproductive health and somatic tumor testing businesses, management expects GeneDx to: • Generate pro forma revenues between $170-173 million in 2022, an approximate 37-40% increase from pro forma $123.7 million in 2021;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022"},{"label":"Revenue","value":"$170-173 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"8f1c73a255c8b1ac1eb7022390e4add64a08eca4","claim":"GeneDx Holdings Corp. reported full year 2023 results: revenue $205-220 million. Guidance initiated.","evidence_excerpt":"2023 Guidance (Unaudited) The continuing operations of GeneDx, excluding revenues and costs from exited business activities, are expected to: • Generate revenues between $205-220 million for full year 2023;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$205-220 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"4c861f6e120af9de372e448082308a6713a36f03","claim":"GeneDx Holdings Corp.: Company changed name from Sema4 Holdings Corp. to GeneDx Holdings Corp. via a certificate of amendment to its certificate of incorporation, effective January 9, 2023 (effective 2023-01-09).","evidence_excerpt":"Effective as of January 9, 2023, GeneDx Holdings Corp. (the “ Company ”) changed its name from “Sema4 Holdings Corp.” to “GeneDx Holdings Corp.” (the “ Name Change ”) pursuant to a certificate of amendment to its certificate of incorporation (the “ Certificate of Amendment ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-01-09"}],"fact_type":"governance_change"},{"claim_id":"bf97022352aae0a9003f86e54d193f1308feaf69","claim":"GeneDx Holdings Corp.: Board adopted amended and restated bylaws effective January 9, 2023, incorporating updates for name change, universal proxy rules, DGCL changes, and other revisions (effective 2023-01-09).","evidence_excerpt":"the Board also approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), effective as of January 9, 2023, in connection with the Name Change as well as the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the DGCL, and a periodic review of the bylaws of the Company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000006/0001818331-23-000006-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-01-09"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}